Skip to main content

Table 2 Secondary outcomes

From: Efficacy of convalescent plasma for the treatment of severe influenza

Secondary outcomes Author H-IVIG/immune plasma group Control group P value
Antibody levels Davey Jr., et al., 2019 [17]
Group IFIPS, 2016 [21]
Significantly increases HAI titer levels among patients with influenza A and B
Viral loads Hung et al., 2013 [18] 3.3 log 10 copies/mL(H1N1) 4.67 log 10 copies/mL 0.04
Davey Jr., et al., 2019 [17] Mean log10 RNA − 1.95(Influenza A) − 2.62 0.02
Davey Jr., et al., 2019 [17] Mean log10 RNA − 2.09(influenza B) − 1.54 0.005
Beigel et al., 2017 [22] Median log 10 copies per mL 1.9 (1.9–1.9) day 7 (Nasal swab, Influenza A and B) 1.9 (1.9–1.9) NS
Cytokines Hung et al., 2013 [18] TNF-a, IL-1ra, and IL-10 fell to a similar level as control 3 days after treatment
Mechanical ventilation, day Beigel et al., 2017 [22] 0 (0–6) (influenza A and B) 3 (0–14) 0.14
Beigel et al., 2019 [16] 9 (4–16) (influenza A) 15.5 (7.0–29.0) 0.22
Length of ICU stay, day Hung et al., 2013 [18] 11 (4–13.5) (H1N1) 10 (4.5–13.5) NS
Beigel et al., 2017 [22] 2.5 (0.0–9.0) (influenza A and B) 3 (0–13) 0·37
Beigel et al., 2019 [16] 5.0(3.0–12.5) (influenza A) 8 (4–25) 0.32
Length of hospital stay, day Hung et al., 2013 [18] 16 (11.5–13.5) (H1N1) 16 (7–29) NS
Beigel et al., 2017 [22] 6 (4–16) (influenza A and B) 11 (5–25) 0·13
Beigel et al., 2019 [16] 5 (3–12) (influenza A) 6 (4–12) 0.30
Serious adverse events Beigel et al., 2017 [22] 20% (influenza A and B) 38% 0·041
Beigel et al., 2019 [16] 35% (influenza A) 32% NS